End-stage Renal Disease and Hemodialysis Characteristics of the Study Population as a Whole and According to Ankle–Brachial Index (ABI) Status.
End-stage Renal Disease and Hemodialysis Characteristics of the Study Population as a Whole and According to Ankle–Brachial Index (ABI) Status.
| Characteristic | Overall (n=85) | Abnormal ABI (n=43) | Normal ABI (n=42) | P |
|---|---|---|---|---|
| Hemodialysis sessions/week, n (%) | 0.752 | |||
| 3 times | 36 (42.4) | 18 (41.9) | 18 (42.8) | |
| 2 times | 39 (45.9) | 21 (48.8) | 18 (42.9) | |
| 1 time | 10 (11.8) | 4 (9.3) | 6 (14.3) | |
|
| ||||
| Geriatric nutritional risk index | 101.3±13.6 | 100.7±11.9 | 102.0±15.2 | 0.653 |
|
| ||||
| Hemodialysis duration, month | 10.0 (5.0–18.5) | 10.0 (5.0–19.0) | 10.5 (5.0–18.3) | 0.870 |
|
| ||||
| Initial nephropathy, n (%) | 0.564 | |||
| Chronic glomerulonephritis | 25 (29.4) | 11 (25.7) | 14 (33.3) | |
| Diabetic nephropathy | 30 (35.3) | 17 (39.5) | 13 (31.0) | |
| Nephroangiosclerosis | 23 (27.1) | 10 (23.3) | 13 (31.0) | |
| Others | 7 (8.3) | 2 (4.7) | 0 (0.0) | |
|
| ||||
| Interdialytic weight gain, kg | 1.96±0.83 | 1.79±0.78 | 2.1±0.9 | 0.050 |
|
| ||||
| Medications, n (%) | ||||
| Ca/Vit D supplement, n (%) | 45 (52.9) | 23 (53.5) | 22 (52.4) | 0.546 |
| Erythropoietin, n (%) | 62 (72.9) | 34 (79.1) | 28 (66.7) | 0.149 |
| Iron, n (%) | 67 (78.8) | 36 (83.7) | 31 (73.8) | 0.197 |
| Phosphorus binders, n (%) | 11 (12.9) | 6 (14.0) | 5 (11.9) | 0.517 |
|
| ||||
| MICS, n (%) | 32 (37.6) | 16 (37.2) | 16 (38.1) | 0.555 |
|
| ||||
| Residual diuresis, mL/day | 490 (300–700) | 470 (300–900) | 495.0 (300–612.5) | 0.704 |
|
| ||||
| Vascular access, n (%) | 0.056 | |||
| Arteriovenous fistula | 3 (3.5) | 2 (4.7) | 1 (2.4) | |
| Permanent catheter | 8 (9.4) | 1 (2.3) | 7 (16.7) | |
| Temporary catheter | 74 (87.1) | 40 (93.0) | 34 (81.0) | |
|
| ||||
| Weekly urea clearance | 1.13±0.23 | 1.13±0.24 | 1.13±0.22 | 0.979 |